Nomogram for Overall Survival of Japanese Patients with Bone Metastatic Prostate Cancer

Abstract

Objective: We analyzed the relationship between prostate cancer outcome and pretreatment clinical factors, and developed a prognostic nomogram for Overall Survival (OS) of patients with bone metastasis. Methods:Beginning in 1993 to 2011, 463 consecutive prostate cancer patients with bone metastasis were treated. Data sets from 361 patients were used to develop the nomogram (training data), and data sets of 102 patients were used for validation of the nomogram (validation data). Using the external validation data set, the nomogram was assessed for discriminatory ability, and the predictions were assessed for calibration accuracy by plotting actual survival against predicted risk.Results: Of 361 training data set, 205 (56.8%) patients died, 169 (46.8%) deaths of which were due to prostate cancer. The Median follow-up of patients were 55.2 months. In multivariate analysis, patient age, serum PSA, clinical T stage, extent of disease on bone scan (EOD), and biopsy Gleason sum were independent prognostic factors. We developed a prognostic model for prostate cancer patients with bone metastasis, consisting of these five factors. This nomogram can be used to estimate 1-, 3-, and 5-year survival probability. External validation of this model using 102 validation data sets showed reasonable accuracy (c-index 0.719), although with slight underestimation. Conclusion:Our pretreatment prognostic nomogram might be useful for Japanese prostate cancer patients with bone metastasis.

Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer

“…Because patients with mHNPC have various survival risks [21], survival risk classifications before treatment may provide useful information for selecting treatment strategies. Previously, we reported that mHNPC patients with high LMW-PTP expression had shorter overall survival than did patients with low expression [8].…”

Impact of age at diagnosis of de novo metastatic prostate cancer on survival

“…15 In another series, age was further confirmed to be an independent prognostic factor for OS in men with mPCa, and when it was incorporated into a pretreatment prognostic nomogram, age had reasonable discriminatory performance. 16 However, such studies were performed before the development and approval of many life-prolonging therapies for metastatic castration-resistant prostate cancer (mCRPC), including drugs targeting the androgen receptor signaling axis (abiraterone and enzalutamide), chemotherapy (docetaxel, cabazitaxel), and radiopharmaceuticals (radium-223). More recently, standards of care have changed such that ADT and docetaxel or ADT and abiraterone are now used earlier in the mHSPC setting, and this further improves survival.…”

Survival analysis and development of a prognostic nomogram for bone‐metastatic prostate cancer patients: A single‐center experience in Indonesia

“…Their nomogram showed that a lower PSA level contributed to higher total points, therefore there was a worse prognosis. 20 We analyzed PSA as a continuous variable, which is similar to the Miyoshi et al nomogram. The J-CAPRA database supports the present findings.…”